The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Exogenous Testosterone or Testosterone with Finasteride Increases Bone Mineral Density in Older Men with Low Serum Testosterone
Abstract
Older men, particularly those with low serum testosterone (T) levels, might benefit from T therapy to improve bone mineral density (BMD) and reduce fracture risk. Concerns exist, however, about the impact of T therapy on the prostate in older men. We hypothesized that the combination of T and finasteride (F), a 5 alpha-reductase inhibitor, might increase BMD in older men without adverse effects on the prostate. Seventy men aged 65 yr or older, with a serum T less than 12.1 nmol/liter on two occasions, were randomly assigned to receive one of three regimens for 36 months: T enanthate, 200 mg im every 2 wk with placebo pills daily (T-only); T enanthate, 200 mg every 2 wk with 5 mg F daily (T+F); or placebo injections and pills (placebo). Low BMD was not an inclusion criterion. We obtained serial measurements of BMD of the lumbar spine and hip by dual x-ray absorptiometry. Prostate-specific antigen (PSA) and prostate size were measured at baseline and during treatment to assess the impact of therapy on the prostate. Fifty men completed the 36-month protocol. By an intent-to-treat analysis including all men for as long as they contributed data, T therapy for 36 months increased BMD in these men at the lumbar spine [10.2 +/- 1.4% (mean percentage increase from baseline +/- SEM; T-only) and 9.3 +/- 1.4% (T+F) vs. 1.3 +/- 1.4% for placebo (P < 0.001)] and in the hip [2.7 +/- 0.7% (T-only) and 2.2 +/- 0.7% (T+F) vs. -0.2 +/- 0.7% for placebo, (P < or = 0.02)]. Significant increases in BMD were seen also in the intertrochanteric and trochanteric regions of the hip. After 6 months of therapy, urinary deoxypyridinoline (a bone-resorption marker) decreased significantly compared with baseline in both the T-only and T+F groups (P < 0.001) but was not significantly reduced compared with the placebo group. Over 36 months, PSA increased significantly from baseline in the T-only group (P < 0.001). Prostate volume increased in all groups during the 36-month treatment period, but this increase was significantly less in the T+F group compared with both the T-only and placebo groups (P = 0.02). These results demonstrate that T therapy in older men with low serum T increases vertebral and hip BMD over 36 months, both when administered alone and when combined with F. This finding suggests that dihydrotestosterone is not essential for the beneficial effects of T on BMD in men. In addition, the concomitant administration of F with T appears to attenuate the impact of T therapy on prostate size and PSA and might reduce the chance of benign prostatic hypertrophy or other prostate-related complications in older men on T therapy. These findings have important implications for the prevention and treatment of osteoporosis in older men with low T levels.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“testosterone has a direct effect on bone through the androgen receptors present in osteoblasts that enhance bone proliferation [46–50], or it has an indirect effect through the aromatization changes to estrogen [51].”
From The Effect of Tobacco Smoking on Bone Mass: An Overview of Pathophysiologic Mechanisms (2018) · cites this paper as [48]
In the citing paper
“In trials, patients with low testosterone have demonstrated statistically significant improvements in erectile function, 24 sex drive, 24 anemia, 25 bone mineral density, 26 lean body mass, 27 and depressive symptoms. 24”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [25]
In the citing paper
“Though testosterone therapy improves bone mineral density, lean body mass, erectile function, and anemia, there is inconclusive evidence on the benefits of testosterone therapy on cognitive function, energy levels, blood glucose or lipid levels, and controversy remains around whether testosterone therapy affects the risk of cardiovascular events (6-13).”
From Non-testosterone management of male hypogonadism: an examination of the existing literature (2020) · cites this paper as [6]
In the citing paper
“Though testosterone therapy improves bone mineral density, lean body mass, erectile function, and anemia, there is inconclusive evidence on the benefits of testosterone therapy on cognitive function, energy levels, blood glucose or lipid levels, and controversy remains around whether testosterone therapy affects the risk of cardiovascular events (6-13).”
From Non-testosterone management of male hypogonadism: an examination of the existing literature (2020) · cites this paper as [6]
In the citing paper
“Though testosterone therapy improves bone mineral density, lean body mass, erectile function, and anemia, there is inconclusive evidence on the benefits of testosterone therapy on cognitive function, energy levels, blood glucose or lipid levels, and controversy remains around whether testosterone therapy affects the risk of cardiovascular events (6-13).”
From Non-testosterone management of male hypogonadism: an examination of the existing literature (2020) · cites this paper as [6]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760
Estrogen Resistance Caused by a Mutation in the Estrogen-Receptor Gene in a Man
Smith, E. P., Boyd, J., Frank, G. R., Takahashi, H., Cohen, R. M., Specker, B., Williams, T. C., Lubahn, D. B., & Korach, K. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410203311604 · Cited by 2,471 · cited 1×
“Furthermore, a second man with an E2 receptor mutation was found to have unfused epiphyses and low BMD (23).”
BackgroundSathianathen, N. (2021) · 50 Studies Every Urologist Should Know · doi:10.1093/med/9780190655341.003.0002 · Cited by 2,080
Feldman, H. A., Longcope, C., Derby, C. A., Johannes, C. B., Araujo, A. B., Coviello, A. D., Bremner, W. J., & McKinlay, J. B. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8201 · Cited by 1,861 · cited 8×
“• Testosterone for Bone Density in Older Men J Clin Endocrinol Metab, February 2004, 89(2):503–510 507”
BackgroundMethodInfluentialSelf-citationEffect of testosterone and estradiol in a man with aromatase deficiency
Carani, C., Qin, K., Simoni, M., Faustini-Fustini, M., Serpente, S., Boyd, J., Korach, K. S., & Simpson, E. R. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707103370204 · Cited by 1,151 · cited 1×
“Treatment with E2 resulted in epiphyseal closure and increased BMD (22).”
BackgroundMcConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L., Albertsen, P., Roehrborn, C. G., Nickel, J. C., Wang, D. Z., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802263380901 · Cited by 1,120
Alendronate for the Treatment of Osteoporosis in Men
Orwoll, E., Ettinger, M., Weiss, S., Miller, P., Kendler, D., Graham, J., Adami, S., Weber, K., Lorenc, R., Pietschmann, P., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008313430902 · Cited by 973 · cited 2×
“The increases in BMD seen in this study are similar in magnitude both to those observed with T therapy in younger hypogonadal men (8–11) and to those seen with bisphosphonate therapy in men with osteoporosis (19, 20).”
Katznelson, L., Finkelstein, J. S., Schoenfeld, D. A., Rosenthal, D. I., Anderson, E. J., & Klibanski, A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954042 · Cited by 791
Falahati-Nini, A., Riggs, B. L., Atkinson, E. J., O’Fallon, W. M., Eastell, R., & Khosla, S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10942 · Cited by 757 · cited 1×
“This “antiresorptive” effect of T also might be mediated by E2 (29) and is a main mechanism by which E2 is thought to increase BMD in postmenopausal women (30).”
BackgroundEffects of Testosterone Replacement in Hypogonadal Men1
Snyder, P. J., Peachey, H., Berlin, J. A., Hannoush, P., Haddad, G., Dlewati, A., Santanna, J., Loh, L., Lenrow, D. A., Holmes, J. H., et al. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6731 · Cited by 572 · cited 1×
“Subjects in our study did have a higher rate of erythrocytosis than seen in previous trials of T administration in older men using transcutaneous patches (10, 11).”
Result
Cited by
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
“A systematic review of randomized, placebo-controlled trials of 1- to 3-yr duration that evaluated effects on bone mineral density and were published before March 2005 yielded inconsistent and imprecise results (118, 120, 122, 132); these trials showed a moderate treatment effect on lumbar bone mineral density (0.”
ResultSelf-citationAdvances in Male Contraception
Page, S. T., Amory, J. K., & Bremner, W. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0041 · Cited by 1,134
“In older, hypogonadal men, the combination of TE plus finasteride, a specific inhibitor of 5 -reductase type II, maintains the beneficial effects of testosterone on bone mineral density (291), strength, physical performance, lipids, and body composition (292) without precipitating the increases in prostate size or PSA…”
BackgroundSelf-citationThe Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications
Kaufman, J. M., & Vermeulen, A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0013 · Cited by 1,079
“9 yr Baseline T 400 14 ng/dl Increased muscle mass and strength with decreased fat mass (both T and NAN); increased lumbar spine BMD (only T); no effect hip and total body BMD, markers bone turnover; improved overall quality of life (only T) (Qualeffo-41 dedicated questionnaire for osteoporosis patients) Amory, 2004 (…”
BackgroundResultInfluentialBhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
“6); two longer trials (71, 80) showed a moderate treatment effect on lumbar bone mineral density (0.”
BackgroundSelf-citationKhosla, S., Amin, S., & Orwoll, E. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0002 · Cited by 930
Metadata
- Authors
- Amory, J. K., Watts, N. B., Easley, K. A., Sutton, P. R., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L.
- Affiliations
- VA Puget Sound Health Care System (US)
- University of Cincinnati (US)
- Emory University (US)
- University of Washington (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-02
- Volume
- 89
- Issue
- 2
- Pages
- 503-510
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2150101787
- Cited by
- 475
- References
- 34
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 15 · 2023: 11 · 2022: 16 · 2021: 12 · 2020: 16 · 2019: 17 · 2018: 25 · 2017: 17 · 2016: 17 · 2015: 17 · 2014: 26 · 2013: 34 · 2012: 25
- FWCI
- 19.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ag010975-04)
- National Institute on Aging (AG10975)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, finasteride, bone mineral density, androgen deficiency, older men, testosterone enanthate, 5-alpha reductase inhibitors, prostate-specific antigen, prostate volume, bone resorption, deoxypyridinoline, fracture risk, osteoporosis prevention, androgen therapy, prostate cancer risk, hip bone density, lumbar spine bone mineral density
- MeSH terms
- Aged, Drug Therapy, Combination, Enzyme Inhibitors, Humans, Male, Organ Size, Prostate, Testosterone, Bone Density, Prostate-Specific Antigen, Finasteride
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exogenous Testosterone or Testosterone with Finasteride Increases Bone Mineral Density in Older Men with Low Serum Testosterone. https://app.cochat.ai/papers/10.1210/jc.2003-031110
- The paper
- Amory, J. K., Watts, N. B., Easley, K. A., Sutton, P. R., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L. (2004). Exogenous Testosterone or Testosterone with Finasteride Increases Bone Mineral Density in Older Men with Low Serum Testosterone. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2003-031110
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.